earnings
confidence high
sentiment neutral
materiality 0.60
Outlook Therapeutics reports Q3 FY2024 adjusted net loss $19.2M; EU/UK approval for LYTENAVA
Outlook Therapeutics, Inc.
2024-Q3 EPS reported
-$4.82
- GAAP net income $44.4M ($1.91 basic EPS), but diluted loss $0.89; adjusted net loss $19.2M ($0.83).
- Cash and equivalents $32.0M at June 30, 2024; raised $65M from private placements in March/April.
- EU and UK granted marketing authorization for LYTENAVA (bevacizumab gamma) for wet AMD.
- NORSE EIGHT trial enrollment at 359 of ~400 subjects; topline results expected Q4 CY2024.
- BLA resubmission for ONS-5010 on track for Q1 CY2025; US launch anticipated H2 CY2025.